Matthew Dietz
Expertise in
7
conditions

Dr. Matthew Dietz

Hematology | Oncology
Optum
Pediatric Hematology-Oncology
100 N Mario Capecchi Dr, 
Salt Lake City, UT 
On Staff At
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
13 Years of Experience

Expertise in
7
conditions
Optum
Pediatric Hematology-Oncology
100 N Mario Capecchi Dr, 
Salt Lake City, UT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Dr. Dietz received his degrees in medicine and medical education from the University of New England. He completed his Pediatric Residency and Hematology and Oncology Fellowship at Oregon Health & Science University where he also served as chief resident.In 2020 Dr. Dietz joined the faculty of the University of Utah, where he is currently an Assistant Professor of Pediatrics in the Division of Pediatric Hematology and Oncology. Clinically, Dr. Dietz focuses on the care of pediatric and young adult patients with bone and soft tissue sarcoma, as well as children with retinoblastoma. He is the Associate Director of the Primary Children's Hospital Solid Tumor Program and leads the Comprehensive Retinoblastoma Program. Dr. Dietz is committed to delivering cutting edge clinical care, as well as providing patients with access to experimental therapeutics and discovery programs. Dr. Dietz's research efforts include team science approaches to better understand the biology driving cancer progression and treatment resistance with a focus on translating this work into new therapies. He is a member of the Huntsman Cancer Institute's Experimental Therapeutics Program and actively involved in the development of early phase clinical trials through multiple cooperative consortia including the Children's Oncology Group, The Sunshine Project, the Pediatric Oncology Experimental Therapeutics Investigator's Consortium, and the Pediatric Early Phase Clinical Trial Network.

Dr. Dietz is highly rated in 7 conditions, according to our data. His top areas of expertise are Ewing Sarcoma, Langerhans Cell Histiocytosis, Reticulohistiocytoma, Histiocytosis, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 9 peer reviewed articles and participating in 20 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of New England Portland Campus, 2013
Residency
Oregon Health & Science University-OHSU GME
Specialties
Hematology
Oncology
Licenses
Pediatrics in OR
Board Certifications
American Board Of Pediatrics
Fellowships
Oregon Health & Science University-OHSU GME
Hospital Affiliations
Primary Children's Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
BridgeSpan
  • EPO
  • HMO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Regence
  • EPO
  • PPO
SelectHealth
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 4 Less Insurance Carriers -

Locations

Pediatric Hematology-oncology
100 N Mario Capecchi Dr, Salt Lake City, UT 84113
Call: 801-662-4700
Other Locations
Pediatric Hematology-oncology - University Of Utah Hospital
50 N Medical Dr, Salt Lake City, UT 84132
Call: 801-662-4700
Pediatric Hematology-oncology - Hci
1950 Circle Of Hope Dr, Salt Lake City, UT 84112
Call: 801-587-4745

Additional Areas of Focus

Dr. Dietz has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


20 Clinical Trials

A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
Enrollment Status: Recruiting
Publish Date: December 22, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Bleomycin, Bleomycin Sulfate, Carboplatin, Cisplatin, Etoposide, Etoposide Phosphate
Study Phase: Phase 3
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Other, Drug
Study Drug: Ensartinib
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Procedure, Drug, Other
Study Drugs: Ensartinib, Erdafitinib, Larotrectinib, Olaparib, Palbociclib, Samotolisib, Selpercatinib, Selumetinib Sulfate, Tazemetostat, Tipifarnib, Ulixertinib, Vemurafenib
Study Phase: Phase 2
A Safety, Pharmacokinetic and Efficacy Study of a y-Secretase Inhibitor, Nirogacestat (PF-03084014), in Children and Adolescents With Progressive, Surgically Unresectable Desmoid Tumors
A Safety, Pharmacokinetic and Efficacy Study of a y-Secretase Inhibitor, Nirogacestat (PF-03084014), in Children and Adolescents With Progressive, Surgically Unresectable Desmoid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 02, 2026
Intervention Type: Other, Procedure, Drug
Study Drug: Nirogacestat
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations
Enrollment Status: Active_not_recruiting
Publish Date: January 29, 2026
Intervention Type: Drug
Study Drug: Ivosidenib
Study Phase: Phase 2
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab With or Without Eflornithine (DFMO) in Children With Relapsed, Refractory or Progressive Neuroblastoma
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab With or Without Eflornithine (DFMO) in Children With Relapsed, Refractory or Progressive Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: January 21, 2026
Intervention Type: Drug, Biological
Study Drugs: Dinutuximab, Eflornithine Hydrochloride, Irinotecan Hydrochloride, Sargramostim, Temozolomide
Study Phase: Phase 2
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Enrollment Status: Active_not_recruiting
Publish Date: December 22, 2025
Intervention Type: Drug, Other, Procedure
Study Drugs: Carboplatin, Cisplatin, Doxorubicin, Etoposide, Fluorouracil, Gemcitabine, Irinotecan, Oxaliplatin, Sorafenib, Vincristine Sulfate
Study Phase: Phase 3
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Drug
Study Drug: Tipifarnib
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Procedure, Drug
Study Drug: Selpercatinib
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions
Enrollment Status: Active_not_recruiting
Publish Date: December 03, 2025
Intervention Type: Procedure, Drug
Study Drugs: Larotrectinib, Larotrectinib Sulfate
Study Phase: Phase 2
A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
Enrollment Status: Active_not_recruiting
Publish Date: December 03, 2025
Intervention Type: Drug, Biological
Study Drugs: Axitinib, Nivolumab
Study Phase: Phase 2
Larotrectinib (LOXO-101, NSC# 788607) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias
Larotrectinib (LOXO-101, NSC# 788607) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias
Enrollment Status: Active_not_recruiting
Publish Date: December 02, 2025
Intervention Type: Drug
Study Drug: Larotrectinib Sulfate
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Erdafitinib in Patients With Tumors Harboring FGFR1/2/3/4 Alterations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Erdafitinib in Patients With Tumors Harboring FGFR1/2/3/4 Alterations
Enrollment Status: Active_not_recruiting
Publish Date: December 02, 2025
Intervention Type: Procedure, Other, Drug
Study Drug: Erdafitinib
Study Phase: Phase 2
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Radiation, Drug, Biological, Other
Study Drugs: Cyclophosphamide, Dactinomycin, Irinotecan hydrochloride, Temsirolimus, Vincristine sulfate, Vinorelbine
Study Phase: Phase 3
Evolutionary Inspired Therapy for Newly Diagnosed, Metastatic, Fusion Positive Rhabdomyosarcoma
Evolutionary Inspired Therapy for Newly Diagnosed, Metastatic, Fusion Positive Rhabdomyosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: November 26, 2025
Intervention Type: Drug
Study Drugs: Vincristine, Cyclophosphamide, Vinorelbine, Actinomycin D, Cyclophosphamide pill
Study Phase: Phase 2
A Pilot Study of Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide in the Post-Consolidation Setting for High-Risk Neuroblastoma
A Pilot Study of Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide in the Post-Consolidation Setting for High-Risk Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: October 27, 2025
Intervention Type: Procedure, Drug, Radiation, Biological
Study Drugs: Dinutuximab, Irinotecan, Isotretinoin, Sargramostim, Temozolomide
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of LY3023414 in Patients With Solid Tumors
NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of LY3023414 in Patients With Solid Tumors
Enrollment Status: Completed
Publish Date: January 27, 2025
Intervention Type: Procedure, Drug
Study Drug: Samotolisib
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Vemurafenib in Patients With Tumors Harboring BRAF V600 Mutations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Vemurafenib in Patients With Tumors Harboring BRAF V600 Mutations
Enrollment Status: Completed
Publish Date: January 27, 2025
Intervention Type: Other, Drug
Study Drug: Vemurafenib
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- A Phase 2 Subprotocol of Olaparib in Patients With Tumors Harboring Defects in DNA Damage Repair Genes
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- A Phase 2 Subprotocol of Olaparib in Patients With Tumors Harboring Defects in DNA Damage Repair Genes
Enrollment Status: Completed
Publish Date: December 11, 2024
Intervention Type: Drug
Study Drug: Olaparib
Study Phase: Phase 2
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes
Enrollment Status: Completed
Publish Date: November 01, 2024
Intervention Type: Other, Drug
Study Drug: Palbociclib
Study Phase: Phase 2
View 19 Less Clinical Trials

9 Total Publications

Consensus recommendations regarding local and metastasis-directed therapies in the management of relapsed/recurrent Ewing sarcoma.
Consensus recommendations regarding local and metastasis-directed therapies in the management of relapsed/recurrent Ewing sarcoma.
Journal: Cancer
Published: October 28, 2024
View All 9 Publications
Similar Doctors
Michael Pulsipher
Expertise in
16
conditions
Dr. Michael Pulsipher
Hematology | Oncology
Expertise in
16
conditions
Dr. Michael Pulsipher
Hematology | Oncology

Pediatric Bone Marrow Transplant

100 N Mario Capecchi Dr, 
Salt Lake City, UT 
 (0.1 miles away)
801-662-4700
Experience:
36+ years
Languages Spoken:
English
See accepted insurances

Dr. Pulsipher is currently the Division Chief of the Pediatric Hematology at Intermountain Primary Children's Hospital and Oncology, Director of the Children's and Adolescent Cancer Initiative at Huntsman Cancer Institute and a Presidential Chair in Pediatric Oncology and Hematology at the University of Utah.  Dr. Pulsipher is an internationally recognized expert in Bone Marrow Transplantation and Cellular Therapy, having directed the world's largest pediatric transplant research group for more than a decade (Pediatric Transplantation and Cellular Therapy Consortium).  He has run more than 20 multicenter trials in the field and is considered and expert in broad areas of transplantation and cellular therapy.  Areas of focus have included development of reduced toxicity approaches to transplantation of both malignant and non-malignant disorders with a focus on minimizing short and long-term effects of transplant.  For non-malignant disorders he has run national protocols that have improved safety for patients with immunodeficiencies, HLH, and bone marrow failure. For cancer, he has developed techniques allowing identification of patients who can avoid radiation-based treatments for leukemia.  This has included a novel approach to safer transplantation of patients using half-matched family donors (haploidentical donors) using a novel form of bone marrow graft engineering called alpha-beta T-cell depletion.  His desire to develop safer approaches has become a major focus as he has led major studies in the field of chimeric antigen receptor T-cells (CAR T-cells), a safer approach to cancer cure.  Dr. Pulsipher's work in cell therapy helped lead to the FDA approval of the first CART cell treatment, tisagenlecleucel, and he continues to run trials in CAR T, NK, and Viral Specific T-cell therapies. He has open protocols aimed at improving outcomes and his lab efforts are focused on making CAR T-cells that last longer and avoid overcome resistance by cancer cells. Dr. Pulsipher's interests have included ensuring that the families of those undergoing transplantation and cell therapy are psychologically well throughout the process.  To help with this, he has run several large trials assessing the safety and Quality of Life of pediatric bone marrow donors and is he currently running a large national trial looking at the psychological well-being of donor and recipient families as they go through the transplant process.For questions regarding Dr. Pulsipher's adult practice at the Huntsman Cancer Institute, or for questions about any of our clinical programs and for assistance identifying the right Hematology specialist for you or your family member, please contact our Clinical Care Specialist/New Patient Coordinator at (801) 587-4652. For questions regarding Dr. Pulsipher's pediatric practice and the Blood and Marrow Transplant Program at Primary Children's Medical Center, please call (801) 662-4830. Dr. Pulsipher is highly rated in 16 conditions, according to our data. His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Graft Versus Host Disease (GvHD), Leukemia, Severe Combined Immunodeficiency (SCID), and Bone Marrow Transplant.

Expertise in
5
conditions
Dr. Elizabeth Raetz
Hematology | Oncology
Expertise in
5
conditions
Dr. Elizabeth Raetz
Hematology | Oncology

Pediatric Hematology-Oncology

100 N Mario Capecchi Dr, 
Salt Lake City, UT 
 (0.1 miles away)
801-662-4700
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Elizabeth Raetz is a Hematologist and an Oncologist in Salt Lake City, Utah. Dr. Raetz is highly rated in 5 conditions, according to our data. Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Adult T-Cell Leukemia, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Raetz is currently accepting new patients.

Expertise in
12
conditions
Dr. Hassan Yaish
Hematology | Oncology
Expertise in
12
conditions
Dr. Hassan Yaish
Hematology | Oncology

Office

127 S 500 E Ste 600, 
Salt Lake City, UT 
 (2.0 miles away)
801-581-2121
Languages Spoken:
English
See accepted insurances

Hassan Yaish is a Hematologist and an Oncologist in Salt Lake City, Utah. Dr. Yaish is highly rated in 12 conditions, according to our data. His top areas of expertise are Pyruvate Kinase Deficiency, Hemolysis, Hereditary Spherocytosis, Anemia, and Splenectomy.

VIEW MORE Hematologists

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dietz's expertise for a condition
ConditionClose
      • Advanced
      • Ewing Sarcoma
        Dr. Dietz is
        Advanced
        . Learn about Ewing Sarcoma.
        See more Ewing Sarcoma experts
      • Hepatoblastoma
        Dr. Dietz is
        Advanced
        . Learn about Hepatoblastoma.
        See more Hepatoblastoma experts
      • Histiocytosis
        Dr. Dietz is
        Advanced
        . Learn about Histiocytosis.
        See more Histiocytosis experts
      • Langerhans Cell Histiocytosis
        Dr. Dietz is
        Advanced
        . Learn about Langerhans Cell Histiocytosis.
        See more Langerhans Cell Histiocytosis experts
      • Osteosarcoma
        Dr. Dietz is
        Advanced
        . Learn about Osteosarcoma.
        See more Osteosarcoma experts
      • Reticulohistiocytoma
        Dr. Dietz is
        Advanced
        . Learn about Reticulohistiocytoma.
        See more Reticulohistiocytoma experts
      View All 7 Advanced Conditions
      • Experienced
      • Adult Soft Tissue Sarcoma
        Dr. Dietz is
        Experienced
        . Learn about Adult Soft Tissue Sarcoma.
        See more Adult Soft Tissue Sarcoma experts
      • Bone Marrow Aspiration
        Dr. Dietz is
        Experienced
        . Learn about Bone Marrow Aspiration.
        See more Bone Marrow Aspiration experts
      • Denys-Drash Syndrome (DDS)
        Dr. Dietz is
        Experienced
        . Learn about Denys-Drash Syndrome (DDS).
        See more Denys-Drash Syndrome (DDS) experts
      • Embryonal Tumor with Multilayered Rosettes
        Dr. Dietz is
        Experienced
        . Learn about Embryonal Tumor with Multilayered Rosettes.
        See more Embryonal Tumor with Multilayered Rosettes experts
      • Glioma
        Dr. Dietz is
        Experienced
        . Learn about Glioma.
        See more Glioma experts
      • Intersex
        Dr. Dietz is
        Experienced
        . Learn about Intersex.
        See more Intersex experts
      View All 9 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile
      1. Homepage
      2. Hematologists Salt Lake City, UT
      3. Dr. Matthew Dietz
      For Patients
      • Our Story
      • How MediFind Works
      • Conditions A-Z
      • Doctor Directory
      • Symptoms Directory
      • Procedures Directory
      • Treatment Directory
      • Drug Directory
      • Infusion Center Finder
      • FAQ
      • Contact Us
      For Providers and Practices
      • Claim Your Profile
      • Newsroom
      Business Solutions
      • Provider
      • Network Solutions
      Additional Resources
      • Consumer Health Data Privacy Policy
      • Privacy Policy
      • Terms of Use
      • Advertising Policy
      • Content Policy
      Subscribe to our newsletter

      Sign up to stay informed about MediFind and get wellness sent your way.

      Close

        By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

        Bullet PinMediFind
        Follow us on
        This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
        © 2026 All Rights Reserved

        Request an Appointment

        If you are experiencing a medical emergency, call 9-1-1.

        Once you submit your request, MediFind will reach out to the provider’s office to help schedule your appointment. Note that this is not a confirmed booking. You’ll receive a status update via email within 1–2 business days.

        Patient Details

        This information is for the patient who will be seen at the appointment.

            Close

            Returning patient? Use your address on file with the provider.

            Insurance Details

            Please provide information of the primary insurance holder as the practice may require this information to schedule.

            Insurance Provider *
            Insurance ProviderClose

            Appointments Details

            Let’s get more information about your appointment.

                    0 / 1000
                    By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.